Literature DB >> 31794468

Toxic Myopathies.

Christopher T Doughty, Anthony A Amato.   

Abstract

PURPOSE OF REVIEW: This article reviews the pathogenesis, clinical features, and management of toxic myopathy related to common medications, critical illness, and illicit substances. RECENT
FINDINGS: Muscle symptoms are common among statin users and are usually reversible after discontinuation of the statin; rarely, however, statins trigger an immune-mediated necrotizing myopathy that persists and requires immunomodulatory therapy. Autoantibodies targeting 3-hydroxy-3-methylglutaryl coenzyme A reductase can distinguish the toxic and immune-mediated forms. Immune checkpoint inhibitors, increasingly used in the treatment of advanced cancer, have recently been associated with the development of inflammatory myositis. A reversible mitochondrial myopathy has long been associated with zidovudine, but recent reports elucidate the risk of myopathy with newer antivirals, such as telbivudine and raltegravir.
SUMMARY: The medications most commonly associated with myopathy include statins, amiodarone, chloroquine, hydroxychloroquine, colchicine, certain antivirals, and corticosteroids, and myopathy can occur with chronic alcoholism. Certain clinical, electrodiagnostic, and histologic features can aid in early recognition. Stopping the use of the offending agent reverses symptoms in most cases, but specific and timely treatment may be required in cases related to agents that trigger immune-mediated muscle injury.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31794468     DOI: 10.1212/CON.0000000000000806

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  7 in total

1.  Skeletal Muscle Manifestations and Creatine Kinase in COVID-19.

Authors:  Sarah A Friedman; Zeinab Charmchi; Michael Silver; Nuri Jacoby; Jonathan Perk; Yaacov Anziska
Journal:  Neurohospitalist       Date:  2022-06-01

2.  The impact of SARS-CoV-2 on skeletal muscles.

Authors:  Maria Rita De Giorgio; Stefania Di Noia; Cinzia Morciano; Diana Conte
Journal:  Acta Myol       Date:  2020-12-01

3.  Case Report: Orbital Myositis and Myasthenia Gravis as Symptoms of Immune Reconstitution Inflammatory Syndrome in a Patient With Human Immunodeficiency Virus Infection.

Authors:  Yanli Wang; Ning Zhao; Jun Yang; Ying Wen
Journal:  Front Immunol       Date:  2020-12-14       Impact factor: 7.561

Review 4.  Management of musculoskeletal pain in patients with idiopathic pulmonary fibrosis: a review.

Authors:  Svetlana Kašiković Lečić; Jovan Javorac; Dejan Živanović; Aleksandra Lovrenski; Dragana Tegeltija; Jelena Zvekić Svorcan; Jadranka Maksimović
Journal:  Ups J Med Sci       Date:  2022-07-11       Impact factor: 2.646

5.  Artemisinin-Based Combination Therapy Synergized with Medicinal Plants to Induce Musculotoxic Effects.

Authors:  Thérèse Daubrey-Potey; Valéry Adjogoua; Mamadou Kamagaté; Serges Aoussi; Mireille Dosso
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-08       Impact factor: 2.629

6.  Muscle involvement in SARS-CoV-2 infection.

Authors:  Lea Pitscheider; Mario Karolyi; Francesco R Burkert; Raimund Helbok; Julia V Wanschitz; Corinne Horlings; Erich Pawelka; Sara Omid; Marianna Traugott; Tamara Seitz; Alexander Zoufaly; Elisabeth Lindeck-Pozza; Ewald Wöll; Ronny Beer; Stefanie Seiwald; Rosa Bellmann-Weiler; Harald Hegen; Wolfgang N Löscher
Journal:  Eur J Neurol       Date:  2020-10-25       Impact factor: 6.288

7.  Inflammatory features in sporadic late-onset nemaline myopathy are independent from monoclonal gammopathy.

Authors:  Jantima Tanboon; Akinori Uruha; Yukie Arahata; Carsten Dittmayer; Leonille Schweizer; Hans-Hilmar Goebel; Ichizo Nishino; Werner Stenzel
Journal:  Brain Pathol       Date:  2021-05       Impact factor: 6.508

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.